1. Healthcare

Exploring the importance of Nanotechnology in linking diagnosis with treatment
and development of personalised medicine
EVENT OVERVIEW
MarketsandMarkets conferences are proud to announce its Nanotechnologies in Drug Delivery Congress
on the 27 – 28 April 2015 in London, United Kingdom. Bringing together 150+ industry and nanoscience
related experts from the nanomedicine community in which drug delivery technologies alone are expected to
reach $224 billion by 2017.
The role of technology in the delivery of medicine guarantees revolutionary advances with measuring the size
of the particles in nanometer ranges; this detailed analysis has helped improve the efficiency of drug delivery
on a large scale. The application of drug delivery facilitates advanced treatment of cancer, cardiovascular,
pulmonary, genetic, and infectious diseases and considers assessment and review procedures involved in the
development of gene-based pharmaceuticals.
Bringing together 25+ expert speakers from academia and industry, the two day program will examine key
concerns in drug delivery including Nanotechnology drug enabled drug delivery in HIV therapy, siRNA, and
blood protein analysis as well as exploring nanotechnology in medicine design.
The conference will provide an interactive networking platform to highlight the innovations in one of the
fastest growing drug delivery fields through keynote presentations, interactive panel discussions, case studies
and an exhibition area where leading industry providers will showcase their products and services.
1
CONFIRMED SPEAKERS
1. Paul Stannard, Chairman, World Nano Foundation
2. Dr. Haydar Jaafar, Global Head – General Medical Devices, BSI Healthcare, UK
3. P
rof. Dr. Patrick Hunziker, MD, University Hospital Basel, CSO, European Foundation for Nanmedicine
(CLINAM) and President, International Society for Nanomedicine (ISNM), Basel, Switzerland
4.
Prof. Andrew Owen, Professor of Molecular and Clinical Pharmacology, University of Liverpool, Chair,
British Society for Nanomedicine, Liverpool, UK
5. Ms. Sonia Trigueros, Co-Director Oxford Martin Programme on Nanotechnology (Nanomedicine),
University of Oxford, UK
6.
Nathalie Mignet, CNRS Research Director, Team vectors for molecular imaging and targeted therapy,
University Paris Descartes, Founder, French Society for Nanomedicine, France
7.
John Giannios, President, Hellenic and International Society of Molecular and Genomic Medicine
and Research, Head of Translational Medicine, Cancer Research and Regenerative Medicine of Erasinio
Oncology Hospital, Athens, Greece
8. M
arianne Ashford PhD, Principal Scientist Drug Targeting, Pharmaceutical Development,
AstraZeneca, UK
9.
Prof. Stephen Evans, Head of Molecular and Nanoscale Physics Group & Director of Research and
Innovation, University of Leeds, UK
10.Prof. Dr. Vasilis Ntziachristos – Chair for Biological Imaging, Institute for Biological and Medical
Imaging Technical University of Munich, Germany
11.Dr. Dionysius Douroumis - Director of the Centre for Innovation in Process Engineering and Research
(CIPER), Department of Pharmaceutical, Chemical & Environmental Sciences, University of Greenwich,
UK
12. Prof. Ijoema Uchegbu, Chair in Pharmaceutical Nanoscience, UCL School of Pharmacy, UK
13. Andrea Masotti, Gene Expression - Microarrays Laboratory, Bambino Gesù Children’s Hospital, IRCCS
14. Dr. Khuloud Al Jamal, Senior Lecturer in Nanomedicine, King’s College London, UK
15. Prof. Albert Mihranyan, Associate Professor & Senior Lecturer - Division of Nanotechnology, Uppsala
University, Sweden
16. Prof. Nicola Tirelli, Professor of Polymers and Biomaterials, University of Manchester, UK
17. Dr. Christine Dufes, Senior Lecturer in Drug Delivery, University of Strathclyde, UK
FOR REGISTRATION, CONTACT
Badri Dash at [email protected]
Tel: +91 20 6725 6057, +91 8411806334
2
Day 1 – 27th April 2015 – Monday
8.00 - Registration & Refreshments
8.50 – Welcome note by MnM & Morning Chair’s opening remarks
KEYNOTE ADDRESS
9.00 The role of Nanomedicine and Targeted Medicine for Personalised Medicine
Exploring the importance of Nanotechnology in linking diagnosis with treatment and development of
personalised medicine
Confirmed Prof. Dr. Patrick Hunziker, MD, University Hospital Basel, CSO, European Foundation for
Nanmedicine (CLINAM) and President, International Society for Nanomedicine (ISNM), Basel, Switzerland
KEYNOTE ADDRESS
9.20 European Medical Devices Regulation of Nanotechnologies in Drug Delivery
Confirmed - Dr. Haydar Jaafar, Global Head – General Medical Devices, BSI Healthcare, UK
SPECIAL ADDRESS
9.40 Growth of innovative drug delivery platforms – Importance & Benefits
•Up to 50 percent of new drugs can’t be taken orally, so the impetus to create innovative delivery
platforms is strong and growing
• Growing demand for medications that can be self-administered at home
• Increase in chronic diseases
Speaker to be announced
10.00 Solution Provider Presentation
For sponsorship opportunities please contact [email protected]
10.30 – Morning refreshments, Poster Presentations and one to one meetings
SPECIAL ADDRESS
11.40 – Mission Nanotechnology 2015
Confirmed – Paul Stannard, Chairman, World Nano Foundation
FOR REGISTRATION, CONTACT
Badri Dash at [email protected]
Tel: +91 20 6725 6057, +91 8411806334
3
SPECIAL ADDRESS
11.55 – Nanotechnology-enabled drug delivery in HIV therapy
• Background to the application of nanomedicine in HIV treatment and pre-exposure prophylaxis
•Development of orally available nanomedicines for antiretroviral dose reduction and
paediatric applications
• Opportunities for cellular and tissue targeting in HIV
Confirmed - Prof. Andrew Owen, Chair - British Society of Nanomedicine, Professor of Pharmacology,
University of Liverpool
PANEL DISCUSSION
12.20 – Successfully sourcing new technologies from both academia and the industry
•Using nanoscale fabrication techniques to investigate the device design with manageable surface
properties as well as devices capable of functioning as biosensors and stimuli-sensitive delivery platforms
•Magneto-electric nanoparticles are being developed as vehicles for delivering and releasing the anti-HIV
drug AZTTP into the brain
• Sugar-sensitive nanoparticles that release glucose can revolutionize diabetes treatment
Confirmed Panelists Dr. Christine Dufes, Senior Lecturer in Drug Delivery, University of Strathclyde, UK
13.05 – Luncheon
14.05 – Solution Provider Presentation
For sponsorship opportunities please contact [email protected]
14.30 Nanotechnology for Medicine: Smart drug delivery systems for cancer therapies
Invited - Ms. Sonia Trigueros, Co-Director Oxford Martin Programme on Nanotechnology (Nanomedicine),
University of Oxford, UK
14.55 – Solution Provider Presentation
For sponsorship opportunities please contact [email protected]
FOR REGISTRATION, CONTACT
Badri Dash at [email protected]
Tel: +91 20 6725 6057, +91 8411806334
4
15.20 – siRNA - Providing a completely new paradigm for disease treatment
• Loading siRNA into silicon nanoparticles to reduce ovarian cancer
•Developing a wide range of non-viral nanoparticles (ranging in size from 100–400 nm) capable of
delivering siRNA to its target cell without eliciting toxic or immune-mediated side effects
• Human clinical trials
Invited: Prof. Dr. Vasilis Ntziachristos, Director, Institute for Biological and Medical Imaging, Germany
15.45 - Imaging Nanotechnologies fate in vivo: a help to faster drug delivery preclinical studies
Confirmed - Nathalie Mignet, CNRS Research Director, Team vectors for molecular imaging and targeted
therapy, University Paris Descartes, Founder, French Society for Nanomedicine
16.10 – Coffee, Poster Presentations & one on one meetings
16.50 - Blood protein analysis - Providing a sensitive assessment of health and disease with detection
of blood molecular fingerprints
• Cancer cell fingerprints in the blood can speed up childhood cancer diagnosis
•Different types of tumour could be identified using a blood test which recognises the unique fingerprints
produced by tumours
Speaker to be announced
17.15 – Application of Nanoparticles for Discovery of Biomarkers
•Biomarker harvesting is an underutilized application of nanoparticle technology and is likely to undergo
substantial growth.
•Functional polymer-coated nanoparticles can be used for quick detection of biomarkers and DNA
separation.
Speaker to be announced
17.40 – Biocompatible polymers to deliver drugs
• Using polymers for controlled drug release
• Design predictable, controlled delivery of bio active agents
• Natural V/S Synthetic polymers
Speaker to be announced
18.05 – End of Day 1 & Drinks reception
FOR REGISTRATION, CONTACT
Badri Dash at [email protected]
Tel: +91 20 6725 6057, +91 8411806334
5
DAY 2 – 28TH APRIL 2015 - TUESDAY
8.30 – Registration & Refreshments
SPECIAL ADDRESS
9.00 Personalised cancer medicine mediated by pharmacogenomics and tailored immunotargeting via
nanotechnology
Drug molecules,antisense oligonucleotides or antagomirs can be delivered to tumour cells via
immunotargeting circumventing chemoresistant mechanisms such as MDR-1 of Pgp efflux pumps and
biological milieu interactions via pegylation which circumvents RES elimination elimination.This allows
binding of the immunotargeted nanosomal Trojan Horses onto the overexpressed receptors of tumour
cells which leads to their endocytosis and subsequent intracellular release circumventing genomic and
epigenomic chemoresistant mechanisms leading to the eradication of these metastatic tumour cells via
apoptotic cell death or type I PCD with a subsequent bystander killing effect .
Confirmed - John Giannios, President, Hellenic and International Society of Molecular and Genomic Medicine
and Research, Head of Translational Medicine and Cancer Research
9.25 Mesoporous silica nanoparticles as a drug delivery system for anticancer therapy
Confirmed - Dr. Dionysius Douroumis - Director of the Centre for Innovation in Process Engineering
and Research (CIPER), Department of Pharmaceutical, Chemical & Environmental Sciences, University of
Greenwich, UK
9.45 Solution Provider Presentation
For sponsorship opportunities please contact [email protected]
10.10 – Morning refreshments, Poster Presentations and one to one meetings
11.20 Delivery across blood brain barriers using nanoneedles
The wide variety of available nanotechnologies allows the selection of a nanoscale material with the
characteristics best suited to the therapeutic challenges posed by an individual CNS disorder
Confirmed - Dr. Khuloud Al Jamal, Senior Lecturer in Nanomedicine, King’s College London
FOR REGISTRATION, CONTACT
Badri Dash at [email protected]
Tel: +91 20 6725 6057, +91 8411806334
6
11.45 Polyamine-coated carbon nanotubes allow efficient microRNAs delivery in endothelial cells
The advent of nanotechnology offers novel possibilities for biomedical applications and drug delivery.
Carbon nanotubes (CNTs) have recently gained high popularity as potential drug carriers, therapeutic agents
and for applications in diagnosis. Pristine CNTs are not soluble in aqueous solutions because they have
highly hydrophobic surfaces. Therefore, surface functionalization is required to solubilize CNTs and to render
biocompatibility and low toxicity for their medical applications. CNTs are often functionalized with cationic
molecules or polymers in order to interact electrostatically with negatively charged siRNAs or plasmid DNAs.
In this study, pristine CNTs were functionalized with a high molecular weight (25 kDa) branched
polyethyleneimine (PEI) polymer or polyamidoamine (PAMAM) dendrimer (ethylenediamine core, generation
6.0) to develop two effective delivery systems for transferring microRNA oligonucleotides into endothelial
cells (ECs). We demonstrated that ECs can rapidly internalize the miRNA-carrying CNTs in the cytoplasm and
that polymer-coated-CNTs exhibited lower toxicity than pristine CNTs and pure polymers.
Most importantly, the CNTs mediated the intracellular delivery of functional miR-503, which subsequently
regulates target gene expression and ECs behaviour.
Confirmed A
ndrea Masotti, Gene Expression - Microarrays Laboratory, Bambino Gesù Children’s Hospital,
IRCCS
PANEL DISCUSSION
12.10 Safety Issues of Nanoparticles for Diagnostics
Potential toxic effects are a concern with in vivo use of nanoparticles but not with in vitro diagnostics, which
forms the major portion of laboratory diagnostics. There are environmental concerns about the release of
nanoparticles during manufacturing of nanoparticles and the environmental effects.
Confirmed Panelist
Professor Nicola Tirelli, Professor of Polymers and Biomaterials, University of Manchester, UK
12.45 – Luncheon
13.45 Using Nanomedicines to Address Therapeutic Index Challenges
•
High attrition rates continue to be a challenge in Pharmaceutical Industry
•
Over 70% of attrition is attributed to Therapeutic Index Challenges
•
Ability of Nanomedicines to change drug biodistribution
•
Examples of applications of Nanomedicines to improve Therapeutic Index in Oncology
Confirmed - Marianne Ashford PhD, Principal Scientist Drug Targeting, Pharmaceutical Development ,
AstraZeneca
FOR REGISTRATION, CONTACT
Badri Dash at [email protected]
Tel: +91 20 6725 6057, +91 8411806334
7
14.15 Molecular imaging modalities – Revolutionizing the way we look inside human body
• Classical molecular imaging techniques with its strength & limitations
• Application in oncology, neuroscience, cardiology, gene therapy, cell tracking, and theranostics
• Understanding the challenges involved
Speaker to be announced
14.40 Exploring nanotechnology in medicine design
•Understanding the link between chemistry and the resulting nanoparticle allows for the design of
nanoparticles with pharmaceutically advantageous functions.
• Nanoparticles may be used to deliver peptide drugs to the brain
• Nanoparticles may be used to enable oral absorption of hydrophobic drugs
•Medicines for unmet clinical needs are being developed in which nanotechnology is an integral part of
the final formulation.
Confirmed - Prof. Ijoema Uchegbu, Chair in Pharmaceutical Nanoscience, UCL School of Pharmacy
15.05 – Coffee, Poster Presentations & one on one meetings
CASE STUDY SESSION
15.45 – Porous alkali earth metal carbonates as enhancers of solubility for poorly soluble drugs
•Mesoporous inorganic carriers featuring pores below 50 nm exhibit strong potential to enhance the
solubility and biovailability of poorly soluble Type II and IV drugs by restricting the crystallization inside
nanopores;
•The potential of using mesoporous carbonates of alkali earth metals for drug delivery of Type II and IV
drugs was explored;
•First, the enhanced solubility effect was demonstrated for celecoxib and ketoprofen as model drugs by
controlling the pore size distribution and solid-state properties of calcium carbonate;
•Further, completely new structure of micro/mesoporous magnesium carbonate (Upsalite®) was
developed for drug delivery and other industrial applications;
• The enhanced solubility effect of Upsalite® was demonstrated for ibuprofen as a model Type II drug.
Confirmed - Prof. Albert Mihranyan, Associate Professor & Senior Lecturer, Division of Nanotechnology –
Uppsala University
CLOSING PANEL DISCUSSION
16.10 – Cutting cost on delivery and formulations
Targeted nanoparticles can be highly cost-effective, since thousands of molecules of an imaging or
therapeutic agent can be delivered using a relatively small number of surface targeting agents such as IgGs.
16.45 Conference Close
FOR REGISTRATION, CONTACT
Badri Dash at [email protected]
Tel: +91 20 6725 6057, +91 8411806334
8